苏州必扬医药科技

Beyond Bio-tech is a Suzhou-based biotechnology company dedicated to the discovery and development of innovative small molecule drugs using an advanced AI-driven Structure-Based Drug Design (SBDD) platform. Founded in 2021 by experts from leading global pharmaceutical and computational chemistry firms, the company focuses on challenging targets in oncology and immunology. Their proprietary technology integrates physics-based modeling with machine learning to significantly improve the efficiency and success rate of lead optimization. Beyond Bio-tech's lead programs include highly selective inhibitors for KRAS G12D and SOS1, aimed at treating various solid tumors. The company has secured significant venture capital funding to advance its pipeline toward clinical trials and address unmet medical needs through precise molecular engineering.